The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Focal therapy using high-intensity focused ultrasound for localised prostate cancer.
The prostate is a small gland near a man's bladder. Symptoms of localised prostate cancer include difficulties in passing urine, although the disease is often diagnosed before symptoms develop. Focal therapy using high-intensity focused ultrasound aims to find and destroy only the cancerous parts of the prostate, avoiding treatment of healthy tissue. High-intensity ultrasound is delivered to the tumour areas, which are destroyed through heating. The procedure aims to lower the risk of side effects that can occur when radical treatment is given to the whole of the prostate gland (such as loss of bladder control and sexual function).
M71.1 High intensity focused ultrasound of prostate
Y53.2 Approach to organ under ultrasonic control
Y53.7 Approach to organ under magnetic resonance imaging control
In addition the ICD-10 code C61.X Malignant neoplasm of prostate would be recorded.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.